{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:31:04Z","timestamp":1794475864145,"version":"4.9.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010544","name":"Exelixis Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA\/NV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ygyno.2026.05.003","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:04:53Z","timestamp":1778717093000},"page":"107-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A phase Ib\/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma"],"prefix":"10.1016","volume":"209","author":[{"given":"Kati A.","family":"Turner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carson C.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Ketch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn G.","family":"Dinkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wilbanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Charles A.","family":"Leath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Arend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Toboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2026.05.003_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101672","article-title":"Updates and controversies in the management of uterine serous carcinoma and uterine carcinosarcoma","volume":"35","author":"Toboni","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.05.003_bb0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","article-title":"Integrated molecular characterization of uterine carcinosarcoma","volume":"31","author":"Cherniack","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2026.05.003_bb0015","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2024.12.012","article-title":"Not all uterine carcinosarcomas are created equal: survival outcomes according to molecular characterization of uterine carcinosarcoma","volume":"193","author":"Toboni","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.003_bb0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/IGC.0b013e3181a831fb","article-title":"Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy","volume":"19","author":"Leath","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.003_bb0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ygyno.2021.05.003","article-title":"Uterine carcinosarcomas: from pathology to practice","volume":"162","author":"Toboni","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2026.05.003_bb0030","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.21.02050","article-title":"Randomized phase III trial of paclitaxel and carboplatin versus paclitaxel and ifosfamide in patients with carcinosarcoma of the uterus or ovary: an NRG oncology trial","volume":"40","author":"Powell","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.05.003_bb0035","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1158\/1078-0432.CCR-19-2576","article-title":"Phase II trial of cabozantinib in recurrent\/metastatic endometrial cancer: a study of the Princess Margaret, Chicago, and California consortia (NCI9322\/PHL86)","volume":"26","author":"Dhani","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ygyno.2026.05.003_bb0040","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.003_bb0045","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ygyno.2018.11.017","article-title":"Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028","volume":"152","author":"Varga","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.05.003_bb0050","doi-asserted-by":"crossref","first-page":"206","DOI":"10.20892\/j.issn.2095-3941.2015.0070","article-title":"Relationship of VEGF\/VEGFR with immune and cancer cells: staggering or forward?","volume":"13","author":"Li","year":"2016","journal-title":"Cancer Biol. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2026.05.003_bb0055","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2026.05.003_bb0060","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2026.05.003_bb0065","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1111\/cas.14148","article-title":"Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial","volume":"110","author":"Tamura","year":"2019","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.ygyno.2026.05.003_bb0070","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2217\/fon-2020-0655","article-title":"Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer","volume":"17","author":"Kasherman","year":"2021","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.05.003_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008266","article-title":"Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review","volume":"12","author":"Galle","year":"2024","journal-title":"J. Immunother. Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:00:18Z","timestamp":1794474018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826019785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":15,"alternative-id":["S0090825826019785"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase Ib\/II single-arm study of cabozantinib plus dostarlimab in women with recurrent gynecologic carcinosarcoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}